pH-Sensitive Liposomes for Targeted Lymphoma Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), exhibit diverse side effects and limited efficacy due to genetic subtypes, and existing delivery methods for therapeutics like andrographolide suffer from low solubility and inefficient targeting to cancer cells.
Innovation Solution
Development of pH-sensitive liposomes containing apolipoproteins and andrographolide that target scavenger receptor B-1 (SR-B1) on cancer cells, allowing pH-dependent drug release in the tumor microenvironment for enhanced delivery and apoptosis induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and immunotherapy are used to treat lymphoma, then therapeutic effects are achieved, but diverse side effects occur and efficacy is limited due to genetic subtypes
Solution Approach 1:
The patent applies local quality by designing liposomes with pH-sensitive lipids that remain stable at physiological pH (7.4) but disassemble at acidic pH (6.5-6.8) found in tumor microenvironments. This enables the drug to be delivered specifically to cancer cells while sparing healthy tissues, thereby improving therapeutic efficacy and reducing systemic side effects
Solution Approach 2:
The patent uses apolipoproteins (ApoA-1, ApoA-2, or ApoE) as intermediary targeting molecules on the liposome surface that specifically bind to SR-B1 receptors overexpressed on lymphoma cells. This intermediary mechanism enables selective drug delivery to cancer cells, enhancing efficacy while minimizing off-target side effects
2Reliability
If andrographolide is used as a therapeutic agent, then anti-cancer activity is achieved, but low water solubility limits delivery efficiency
Solution Approach 1:
The patent encapsulates andrographolide within liposomes composed of pH-sensitive lipids forming a flexible bilayer shell. This liposomal encapsulation protects the hydrophobic andrographolide from the aqueous environment, dramatically improving its solubility and delivery efficiency while maintaining its anti-cancer activity
Solution Approach 2:
The patent changes the physical-chemical parameters of andrographolide delivery by transitioning from direct administration of the hydrophobic compound to encapsulation within lipid bilayers. This parameter change in the delivery system enables efficient solubilization and targeted delivery while preserving the drug's therapeutic activity
3Reliability
If pH-sensitive liposomes are designed to release drug in tumor microenvironment, then targeted delivery is improved, but liposome stability in circulation must be maintained
Solution Approach 1:
The patent employs pH-sensitive lipids containing imidazole groups with pKa values tuned to respond to pH changes between 6.5-6.8. At physiological pH (7.4), the lipids remain protonated and form stable liposomes for circulation, while at acidic tumor pH, deprotonation triggers liposome disassembly and drug release, thus achieving both stability and targeted delivery
Solution Approach 2:
The pH-sensitive lipids automatically respond to pH changes in the tumor microenvironment, triggering self-disassembly of the liposome structure and release of the encapsulated drug. This self-service mechanism eliminates the need for external triggers or complex control systems, simplifying the design while achieving targeted delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthetic nanoparticles effectively target and induce apoptosis in lymphoma cells, improving therapeutic efficacy while minimizing side effects and enhancing bioavailability of andrographolide.
Implementation Method 1
the pH sensitive liposome, the synthetic nanoparticle is more susceptible to delivering its payload (e.g., therapeutic, andrographolide), in a target environment, or in other words an local environment which due to the disease or disorder has a pH which is different than the pH of the same environment absent the disease or disorder
Data Source
AI summary
Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and/or preventing cancer. In some embodiments, the synthetic nanoparticles and/or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.